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ABSTRACT INTRODUCTION 
The purpose of this study was to assess whether male 
rats whose testosterone levels were suppressed to castra-
tion levels (<0.5 ng/mL) for a 1-year period by the sus-
tained delivery of orntide acetate, a GnRH antagonist, 
would return to fertility (ie, produce offspring) after se-
rum testosterone returned to control levels. Male rats 
comprising a treatment group (orntide microspheres, 
dose = 27 mg/kg/y), a vehicle control group, and a con-
trol group of proven male breeders were used. For the 
treatment and vehicle control groups, serum orntide and 
testosterone levels were monitored at periodic intervals 
for 14 months from the initiation of treatment. After se-
rum testosterone levels returned to vehicle control levels 
and orntide serum levels were no longer discernible for 
the treated group, each of the animals was housed with 2 
drug-naive, female, proven breeders. All the breeder 
females produced offspring with the exception of 1 fe-
male housed with a male rat from the treatment group 
and the 2 females housed with a single male rat from the 
vehicle control group. The mean size and weight of the 
litters from each group were not statistically different. 
Further, fertility of the offspring from each group was 
assessed. The male and female offspring studied were all 
shown to be fertile. The results suggest that lack of fertil-
ity due to testosterone suppression in male rats is re-
versible after cessation of treatment with the GnRH ana-
log, orntide. 
GnRH superagonists like leuprorelin, triptorelin, gosere-
lin, and buserelin currently administered as long-acting 
dosage forms,1-4 act by hyperstimulation and downregu-
lation of GnRH receptors on the gonadotroph cells of the 
pituitary. These peptides are used for treatment of a vari-
ety of hormone-dependent diseases like prostate cancer 
and endometriosis. Unfortunately, the superagonists 
stimulate luteinizing hormone-releasing hormone 
(LHRH) production, which in turn causes a surge of tes-
tosterone and androgens resulting in a “clinical flare.” 
Eventually, they downregulate receptors, block release 
of LH and follicle stimulating hormone (FSH), and also 
prevent synthesis/release of testosterone or estrogen 
from the gonads.5-7 The superagonists have been suc-
cessfully used in patients, and their safety record is well 
established. In addition, upon cessation of therapy with 
the superagonists, these patients are able to bear chil-
dren. Therefore, return to fertility with commercially 
available GnRH superagonists is not a clinical concern. 
Another class of GnRH analogs, the antagonists, are 
being investigated as potential peptide therapeutics.8-9 
These antagonists nullify the action of native GnRH 
peptides by binding to the GnRH receptors without elic-
iting a pharmacological response and have been shown 
to be devoid of the initial-androgen stimulation charac-
teristics of the superagonists, which appears to be a sig-
nificant benefit over the superagonists.10-11 
 Efforts to administer peptide therapeutics via the oral 
route are hindered by their poor bioavailability due to 
enzymatic degradation and to poor passage through bio-
logical membranes because of a low partition coefficient 
and poor diffusivity. Achieving constant levels of bioac-
tive peptides in vivo would require a controlled rate of 
administration of the therapeutic agent. Formulation of 
peptides as microspheres, using biodegradable polymers, 
has been shown to afford controlled delivery of these 
agents. Biodegradable microspheres are injectable dos- 
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Table 1. Fertility Study Design (F0 Generation)* 
Group Group Description (Age in Months) Treatment Orntide Dose (mg/kg) No. of Males 
I Treated males (17.5) Orntide microspheres 27 6 
II Untreated males (17.5) Vehicle control - 5** 
III Young proven male breeders (5) Drug naive - 5 
*Study conducted with young female proven breeders (age, 5 months). 
**Of the 6 males in the vehicle-control group of the testosterone suppression study, one died at 390 days, presumably of old age.  
 
age forms fabricated from biodegradable and biocom-
patible polymers such as polylactide (PLA) and 
poly(lactide-co-glycolide), which have been used as sur-
gical sutures for more than 30 years and are approved 
for human use by the Food and Drug Administration. 
These systems improve patient compliance by eliminat-
ing the need for frequent administration of peptide.12,13 
In vivo, peptide release from these biodegradable micro-
spheres occurs as a result of hydration, which leads to 
polymer erosion or degradation.14-15 For this reason, con-
trolled-release depot formulations of orntide, a potent 
GnRH antagonist, are being developed. These formula-
tions sustain drug levels in vivo for varying periods of 
time.16 
A previously published study showed that male rats 
treated with 120-day orntide microspheres were able to 
produce offspring upon cessation of treatment.17 The 
goal of the present study was to assess the return to fer-
tility in male rats, post treatment of a 1-year PLA micro-
sphere dosage form of orntide, in comparison to un-
treated vehicle control and younger breeders. In addi-
tion, effects on fertility of the second generation were 
determined. 
 
MATERIALS AND METHODS 
Materials 
Orntide acetate was supplied by California Peptide Re-
search Inc (Napa, CA) and was 99% pure. Polylactide 
(PLA) polymer (MW = 22 kDa) from Boehringer Ingel-
heim (Ingelheim, Germany) was used to formulate the 
microspheres. Orntide microspheres were prepared as 
previously described by solvent extraction.14 
Three-month-old, male, Sprague-Dawley rats, purchased 
from Harlan (Indianapolis, IN), weighing approximately 
300 g were used to study the testosterone suppression due 
to orntide administration in microspheres (treated group). 
The male rats were acclimatized to the housing facility for 
1 week, prior to administration of microspheres and vehi-
cle control. Five-month-old, proven male and female 
breeders (Sprague Dawley) were purchased from the 
same supplier and used to assess fertility. 
All the procedures were approved by the Department of 
Laboratory Animal Research at the University of Ken-
tucky, Lexington, KY. 
 
In Vivo Evaluation of Orntide Microspheres 
Two groups of male Sprague-Dawley rats (n = 6) were 
used in this study. Group I received the 1-year orntide 
microsphere formulation (27 mg orntide/kg/y) prepared 
with the polymer in vehicle (1% sodium carboxymethyl-
cellulose, 2% mannitol, and 0.01% Tween 80). Animals 
in Group II were used as a vehicle control and received 
vehicle alone. The injections were administered subcuta-
neously using a 20-gauge needle at the base of the neck. 
Blood samples were collected from the tail vein at prede-
termined intervals. The serum was separated and frozen 
until analysis. Following the 1-year treatment period, the 
orntide microsphere-treated rats were subjected to a 
washout period until they resumed and maintained similar 
testosterone levels as the vehicle control. 
Serum orntide levels in rats were measured using a ra-
dioimmunoassay.15 Tyrl-orntide was radioiodinated by 
the lactoperoxidase method and the labeled ligand was 
purified by high-performance liquid chromatography 
(HPLC). Orntide was conjugated by the carbodiimide 
method, and the antibody to orntide was produced in 
rabbits. The lower detection limit of the assay was 0.008 
ng/mL. The intra- and interassay coefficients of varia-
tion were 6% and 9%, respectively. 
Serum testosterone levels were assayed using Active 
Testosterone RIA DSL-4000 kits (Diagnostic Systems 
Inc, Webster, TX). The lower detection limit for this 
assay was 0.08 ng/mL and the intra- and interassay coef-
ficients of variation were 10% and 9%, respectively. 
 
Fertility Study (F0 Generation) 
Testosterone levels in male rats from Group I returned to 
normal (similar to Group II) by 390 days. At 438 days, 
after allowing an additional washout period, the males 
were housed with 2 proven breeder females for 1 month 
(Table 1). A proven female breeder is defined as having  
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Figure 1. Testosterone levels for treated and vehicle-control groups. The insert shows the serum orntide levels.
 
given birth to at least 2 offspring. Drug-naive male 
proven breeders (Group III) were also each housed with 
2 female breeders to assess the effect of age on the abil-
ity of male rats to sire offspring. Pregnant females were 
separated from males and housed in separate cages. Af-
ter birth, the number of offspring (males and females) 
was recorded and the offspring were observed for any 
abnormality during weaning (ie, 30 days after birth). 
 
Fertility Study (F1 Generation) 
After weaning, 3 offspring males were randomly se-
lected from each of the 3 F0 generation Groups (I-III). 
Each male was housed with 2 females, a female off-
spring from the F0 generation and a proven mother that 
was used as a positive control. These three groups are 
designated as Groups IV-VI. F0-generation female off-
spring were selected to assess fertility within and be-
tween groups. Pregnant females were separated from 
males and housed in separate cages. After birth, the 
number of offspring (males and females) was recorded 
and the offspring were observed for any abnormality 
during weaning (ie, 30 days after birth). 
 
Statistical Evaluation of Data 
The data are presented as mean ± standard deviation for 
all the analyses performed. For values below the assay 
detection limit, the limit was used for calculations. 
 
RESULTS AND DISCUSSION 
Drug Release and Testosterone Suppression 
Figure 1 shows the testosterone levels in the treated and 
vehicle groups. Testosterone levels were suppressed to 
near 0.5 ng/mL after 6 hours and were below 0.5 ng/mL 
in 1 day. There was no evidence of an elevation of tes-
tosterone, which occurs with the LHRH superagonists. 
The initial burst release of orntide led to a sharp drop in 
testosterone levels followed by a slight elevation, which 
is concurrent with the hydration phase for these micro-
spheres. Testosterone levels remained at approximately 
0.5 ng/mL for 8 days and then gradually declined to 
nondetectable levels by day 60. Full chemical castration 
was achieved from day 15 through day 360 for this 
formulation. 
The insert in Figure 1 shows the in vivo drug levels ob-
tained postadministration of microspheres in the Group I  
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Table 2. F0-Generation Offspring Produced by Male Rats From Groups I to III and Female Proven Breeders 
Number of Offspring 
Female No. 1 Female No. 2 Group (Description) Male, No. 
Male Female Male Female 
1 11 3 2 1 
2 5 5 6 6 
3 8 4 5 9 
4 * * ** ** 
5 7 6 4 8 
I 
(Males treated with orntide microspheres) 
6 7 5 7 5 
1 ** ** ** ** 
2 6 9 8 5 
3 8 4 6 3 
4 4 8 6 5 
II 
(Vehicle-control males) 
5 7 6 8 6 
1 5 10 3 5 
2 5 10 10 4 
3 8 5 4 6 
4 4 6 7 5 
III 
(Drug-naive, male proven breeders) 
5 6 6 5 5 
*Animals sacrificed shortly after birth due to mastitis in the mother. Hence, sex of the offspring was indeterminable. Litter 
size was 11. 
**No offspring.  
 
animals. An initial burst (Cmax = 75 ng/mL at 6 hours) of 
orntide from the microspheres caused a rapid drop in 
serum testosterone levels to below chemical-castration 
level (defined as serum testosterone <0.5 ng/mL). The 
initial burst could be due to the release of peptide associ-
ated with the surface of the microspheres. Following this 
initial burst, serum peptide levels fell sharply, and levels 
remained at 3 to 4 ng/mL up to day 4. This finding may 
be attributed to the time required to hydrate the polymer. 
By day 8, peptide levels rose approximately 7 ng/mL 
and then remained above 4 ng/mL through 180 days. 
Orntide levels declined gradually but were detectable 
until day 360. 
Serum analysis of the vehicle control (data not shown) 
showed no presence of the drug, and this was reflected 
in the testosterone levels (Figure 1). After 390 days, tes-
tosterone levels for the vehicle control and treated 
groups were similar. 
 
Fertility Study 
Figure 1 shows that baseline orntide levels occurred at 
360 and 420 days, and while testosterone levels of 
treated and vehicle-control males were similar at 390 
days, an additional washout period was allowed (study 
started at 438 days). Each treated and vehicle-control 
male was housed with 2 female proven breeders to as-
sess fertility. Young, male proven breeders were also 
used and housed with female proven breeders in a man-
ner similar to the other groups. 
All the male rats treated with orntide microspheres sired 
offspring with at least 1 female proven breeder (Table 
2). The female proven breeders had an average of 12 
offspring, similar to Group III (offspring of male proven 
breeders). One male from the vehicle-control group 
failed to sire any offspring with either female. The rea-
son for this could be disinterest or the inability of the 
female to produce offspring. To assess the fertility of a 
nonmother (female that did not produce any offspring), 
it was housed with a young, drug-naive, male proven 
breeder. Also included in the same cage was a proven 
mother to assess the young male’s ability to sire off-
spring. The other 8 females housed with Group II males 
produced from 9 to 15 pups or an average of 12. There 
was no significant difference in the number of offspring 
produced by the treated rats in comparison with the ve-
hicle-control group and the drug-naive, male proven 
breeders. All the offspring appeared normal, with no 
physical deformities. 
Atkinson et al, in a 2-generation reproductive and fertil-
ity study, reported a fertility index for proven breeder  
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Table 3. F1-Generation Offspring Produced by the F0-Generation Offspring From Groups I to III 
Number of Offspring 
F0-Generation Female 
Offspring 
Female Proven Breeder 
(Control Group) Group (Description) 
F0-Generation Male Off-
spring, No. 
Male Female Male Female 
1 8 9 6 5 
2 3 8 * * 
IV 
(Offspring of males treated with orn-
tide microspheres, Group I)  3 4 1 * * 
1 6 9 4 6 
2 3 5 4 5 
V 
(Offspring of vehicle-control males, 
Group II) 3 0 1 5 3 
1 4 6 7 5 
2 8 6 5 7 
VI 
(Offspring of male proven breeders, 
Group III) 3 4 9 10 4 
*No offspring.  
 
females housed with males and a survival index for the 
offspring at 30 days (see Equations 1-3 below).18 
Fertility Index (Female) =  
 [No. of Females Delivering / 
 No. of Females Cohabited] × 100 
(1) 
Fertility Index (Male) =  
 [No. of Males Siring Offspring / 
 Total No. of Males in the Group] × 100 
(2) 
Survival Index =  
 [No. of Live Offspring at Day 30 / 
 No. of Live Offspring at Day 0] × 100 
(3) 
The fertility indices for males used in the F0-generation 
study were 100%, 80%, and 100%, respectively, for 
Groups I to III. For the females housed with Groups I to 
III, values of 91.6%, 80%, and 100% were obtained. As 
expected, the values were lower for Group II (vehicle-
control group), in which 2 females did not produce any 
offspring when housed with a male. 
The survival indices for the offspring produced in the F0 
generation were 93.7%, 87.0%, and 99.0% for Groups I 
to III, respectively. 
Fertility of nonmothers was assessed by housing with 
male proven breeders. The average number of offspring 
produced in this study was 12 with a range of 10 to 15. 
Fertility and survival indices for the nonmothers used in 
this study were both 100%. All of the offspring showed 
no signs of abnormality at birth. 
A second study was initiated to assess the reproductive 
ability of the F0 generation to verify if orntide could af-
fect the reproductive ability of the offspring. Similar 
studies have been performed on rats exposed to agents 
like mercuric chloride18 and butylated hydroxytoluene 
(BHT),19 and the differences between the 2 generations 
have been reported. 
F0-generation offspring males from Groups I to III were 
able to sire pups with female offspring from the same 
generation (Table 3). Therefore, it may be concluded 
that treatment of one generation of male rats with orntide 
does not affect the reproductive ability of their male and 
female offspring. Fertility indices were 100% for the 
male and female offspring used in this study. The results 
of the fertility and survival indices for both generations 
are shown in Table 4. Also, there is no significant differ-
ence in the number of offspring produced between the 
Groups I to VI. 
For offspring from the F0 and F1 generations, weight was 
recorded at the time of weaning (ie, 30 days). Weight 
gain is frequently used as an indicator of general health 
and development.18 At the time of weaning, there was no 
significant difference in the weights of the litters be-
tween the Groups I to VI, indicating that orntide treat-
ment did not affect the developmental growth of the off-
spring. 
 
CONCLUSION 
A depot formulation of orntide, a GnRH antagonist, ap-
peared to chemically castrate male rats for a 1-year pe-
riod (testosterone < 0.5 ng/mL). Adult male rats that had 
been chemically castrated for a 12-month period were 
able to return to fertility and the number and weight of 
offspring produced were not statistically different from 
the vehicle control and young proven breeders. The re 
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Table 4. Fertility and Survival Indices 
Fertility Index (%) 
Group 
Males Females 
Survival Index for Offspring (%) 
I 
(Males treated with orntide microspheres) 100 91.6 93.7 
II 
(Vehicle-control males) 80.0 80.0 87.0 
III 
(Drug-naive male proven breeders) 100 100 99.0 
IV 
(Offspring of males treated with orntide microspheres, 
Group I)  
100 66.6* 100 
V 
(Offspring of vehicle-control males, Group II) 100 100* 93.6 
VI 
(Offspring of male proven breeders, Group III) 100 100* 100 
*Data presented are for offspring females (F0 generation). 
 
productive ability of chemically castrated rats was pre-
served despite their age. This finding supports the use of 
the GnRH antagonist, orntide, in patients who wish to 
regain their capacity for reproduction after hormonal 
treatment. 
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